[{"id":"92c099b7-baf6-420f-bbb6-7c2961993e03","acronym":"","url":"https://clinicaltrials.gov/study/NCT05674526","created_at":"2023-01-06T15:58:52.282Z","updated_at":"2025-02-25T16:39:35.039Z","phase":"Phase 1","brief_title":"A Phase 1b Study of WU-NK-101 in Combination With Cetuximab","source_id_and_acronym":"NCT05674526","lead_sponsor":"Wugen, Inc.","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • EGFR expression • RAS mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • EGFR expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • WU-NK-101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-07"},{"id":"8b018d8b-943c-40ad-afa1-e87094260581","acronym":"WUN101-01","url":"https://clinicaltrials.gov/study/NCT05470140","created_at":"2022-07-22T11:56:08.417Z","updated_at":"2024-07-02T16:35:37.700Z","phase":"Phase 1","brief_title":"A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05470140 - WUN101-01","lead_sponsor":"Wugen, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WU-NK-101"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-07"}]